SCHEMBL6192056

SCHEMBL6192056

NC(=O)CN1CCCCC1Cc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.47
DPP4 P27487 1/20 0.46
ALDH1A1 P00352 1/20 0.45
LMNA P02545 1/20 0.45
MAPT P10636 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
TAAR1 Q96RJ0 1/20 0.45
DAGLA Q9Y4D2 6/20 0.45
ABHD6 Q9BV23 5/20 0.45
OPRD1 P41143 2/20 0.44
PARP14 Q460N5 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5967654 0.88 LTA4H (0.50) HSD11B1DPP4ALDH1A1LMNAMAPT
SCHEMBL7697264 0.84 ALDH1A1 (0.50) ALDH1A1LMNAMAPTNPSR1TAAR1
SCHEMBL27630337 0.80 PRMT3 (0.44) HSD11B1
SCHEMBL6429540 0.79 HSD11B1 (0.58) HSD11B1DPP4DAGLAABHD6PARP14
Hydrochloric Acid SCHEMBL4766854 0.79 ALDH1A1 (0.57) HSD11B1DPP4ALDH1A1LMNAMAPT
SCHEMBL27492 0.79
SCHEMBL16908331 0.78 CA1 (0.55) DPP4
SCHEMBL8870960 0.78 PRMT3 (0.53) ALDH1A1LMNAMAPTNPSR1TAAR1
SCHEMBL7493746 0.78 KDM4E (0.55) HSD11B1ALDH1A1OPRD1PARP14
SCHEMBL12125006 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1465631-A4 PYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE OSI PHARM INC (US) 2005-03-30 EP disclosed
EP-1465631-A2 PYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE OSI Pharmaceuticals, Inc. (US) 2004-10-13 EP disclosed
WO-2003053366-A2 PYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE OSI PHARMACEUTICALS, INC. (US) 2003-07-03 WO disclosed